Results 121 to 130 of about 7,153 (219)

Complement receptors C5aR1 and C5aR2 differentially influence bone metabolism

open access: yes, 2017
Objectives: Activation of the complement system, a crucial arm of innate immunity, leads to the generation of the anaphylatoxin C5a, acting via its receptors C5aR1 and C5aR2. C5aR1 has already been attributed an important role in bone development, regeneration and inflammation, as C5aR1 expression on[for full text, please go to the a.m. URL]
Hägele, Y   +4 more
openaire   +2 more sources

The Major Role of Type 2 Inflammation in Asthma: From the Perspective of Immunological Mechanism

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
Asthma is a heterogeneous disease that affects individuals of diverse age groups globally and exhibits variable responses to different treatments. Type 2 inflammation contributes to the pathogenesis of asthma through the production of cytokines IL‐4, IL‐5, and IL‐13, thereby inducing characteristic features of asthma such as elevated eosinophil levels ...
Lanying Cheng   +2 more
wiley   +1 more source

EBF1-deficient bone marrow stroma elicits persistent changes in HSC potential

open access: yes, 2020
Crosstalk between mesenchymal stromal cells (MSCs) and hematopoietic stem cells (HSCs) is essential for hematopoietic homeostasis and lineage output. Here, we investigate how transcriptional changes in bone marrow (BM) MSCs result in long-lasting effects
Cauchy, P.   +6 more
core   +1 more source

Evaluating the Real‐World Safety of Ravulizumab in Generalized Myasthenia Gravis: Insights From a Detailed Analysis of FAERS Data

open access: yesJournal of Clinical Pharmacy and Therapeutics, Volume 2026, Issue 1, 2026.
Background Ravulizumab represents the inaugural long‐acting complement C5 inhibitor that has received approval in various countries around the globe for individuals diagnosed with generalized myasthenia gravis (gMG) who are positive for anti‐acetylcholine receptor antibodies.
Yakun Wang   +5 more
wiley   +1 more source

MicroRNA expression, survival, and response to interferon in liver cancer [PDF]

open access: yes, 2009
BACKGROUND: Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease.
Ambs, S   +18 more
core   +1 more source

C5a Increases the Injury to Primary Neurons Elicited by Fibrillar Amyloid Beta

open access: yesASN Neuro, 2017
C5aR1, the proinflammatory receptor for C5a, is expressed in the central nervous system on microglia, endothelial cells, and neurons. Previous work demonstrated that the C5aR1 antagonist, PMX205, decreased amyloid pathology and suppressed cognitive ...
Michael X. Hernandez   +4 more
doaj   +1 more source

C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer

open access: yesNature Communications
Although Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved in multiple diseases, including BRCA1/2 mutant breast cancer, responses are usually transient requiring the deployment of combination therapies for optimal efficacy.
Xi Li   +7 more
semanticscholar   +1 more source

C5aR1 governs Mreg migration, development, and function [PDF]

open access: yesAmerican Journal of Transplantation, 2019
Paloma, Riquelme   +2 more
openaire   +2 more sources

RNA sequencing screening of differentially expressed genes after spinal cord injury

open access: yesNeural Regeneration Research, 2019
In the search for a therapeutic schedule for spinal cord injury, it is necessary to understand key genes and their corresponding regulatory networks involved in the spinal cord injury process.
Yi Li   +7 more
doaj   +1 more source

A guide to chemokines and their receptors [PDF]

open access: yes, 2018
The chemokines (or chemotactic cytokines) are a large family of small, secreted proteins that signal through cell surface G‐protein coupled heptahelical chemokine receptors.
Braun A   +11 more
core   +1 more source

Home - About - Disclaimer - Privacy